.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers recently evaluated zanidatamab gastroesophageal cancer therapy in a groundbreaking Phase 3 trial for HER2-positive patients. This dual HER2-targeted bispecific antibody shows significant promise as a first-line treatment option. Therefore, the study compared zanidatamab, both with and without the anti-PD-1 agent tislelizumab, against the standard-of-care trastuzumab and chemotherapy regimen.
The trial results demonstrate that zanidatamab-based regimens significantly extend progression-free survival. Specifically, patients receiving zanidatamab plus chemotherapy achieved a median progression-free survival of 12.4 months. Similarly, those receiving the triplet combination including tislelizumab also saw a median of 12.4 months. In contrast, the control group receiving trastuzumab and chemotherapy reached only 8.1 months. Consequently, these findings suggest a superior alternative for HER2-positive advanced adenocarcinoma management.
Safety profiles remained manageable across all treatment arms. Although adverse events occurred, they aligned with the known profiles of these specific agents. Furthermore, the overall survival data trended in favor of the zanidatamab groups. As a result, clinicians should consider these results when determining optimal first-line strategies for metastatic gastroesophageal cancer.
Zanidatamab is a bispecific antibody designed to bind two distinct HER2 epitopes. This mechanism enhances HER2 signal blockade and promotes receptor internalization compared to traditional monoclonal antibodies.
In this Phase 3 trial, zanidatamab-based regimens reduced the risk of disease progression or death by approximately 35% to 37% compared to trastuzumab. Both zanidatamab arms showed a median progression-free survival of 12.4 months versus 8.1 months for trastuzumab.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. The information provided should not be used for diagnosing or treating a health problem or disease. Always seek the advice of your physician or another qualified health provider regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Shitara K et al. Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer. N Engl J Med. 2026 May 28. doi: 10.1056/NEJMoa2517729. PMID: 42202319.
ClinicalTrials.gov. A Study of Zanidatamab Plus Chemotherapy With or Without Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastroesophageal Adenocarcinoma (HERIZON-GEA-01). Identifier: NCT05152147.
American Society of Clinical Oncology (ASCO). New Frontiers in HER2-Targeted Therapy for Gastrointestinal Malignancies. 2025.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Zanidatamab combinations significantly improve progression-free survival compared to trastuzumab in HER2-positive gastroesophageal adenocarcinoma....
last month
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
